Top Angle

Leadership

Bottom Angle

Metavention is a venture-backed medical device company founded in 2012 and based in Minneapolis, Minnesota and Orange County, California. The company is leveraging its unique insights into the role of the sympathetic nervous system in diabetes pathophysiology to develop therapies with the potential to transform the treatment of type 2 diabetes. Metavention has assembled a world-class team of engineers, scientists, clinicians and investors to pursue its mission to improve the lives and health of people with type 2 diabetes.

Top Angle

Kevin Hykes

Chairman and Chief Executive Officer

Kevin Hykes is an Operating Partner at Versant Ventures and Chairman and CEO of Metavention, Inc. Kevin was previously President and CEO of Cameron Health, developer of the first and only subcutaneous implantable defibrillator, until its acquisition by Boston Scientific in 2012. Prior to Cameron Health, he was the Chief Commercial Officer of Visiogen, Inc., a venture-backed ophthalmology company which was acquired by Abbott Medical Optics in 2009. Previous to Visiogen, he spent sixteen years at Medtronic, where he held leadership positions in the CRM, Neurological, Heart Valve, and Cardiac Surgery businesses in the US and Europe. Kevin received his MBA from Northwestern University and a BBA from the University of Wisconsin, and is currently on the boards of Veran Medical Technologies and the Courage Kenny Rehabilitation Institute Foundation.

Bottom Angle
Top Angle

Bobak Azamian MD, DPhil

President, Chief Medical Officer, and Founder

Bobby Azamian is the Founder, President and Chief Medical Officer of Metavention. Bobby joined Versant Ventures in 2011, and while at Versant founded Metavention and served as its first President and Chief Executive Officer. Prior to joining Versant, Bobby was a Senior Associate at Third Rock Ventures, where he was actively involved in the building and launch of the firm’s first medical device companies. Previously, Bobby completed residency in internal medicine and practiced as a hospitalist at Brigham and Women’s Hospital while on the faculty of Harvard Medical School. Bobby holds an MD from the Harvard-MIT Division of Health Sciences and Technology; a DPhil in Chemistry from Oxford University as a Rhodes Scholar; and a BA in Physics from Rice University.

Bottom Angle
Top Angle

Tony Vrba

Vice President of Research & Development

Tony Vrba is the Vice President of Research and Development of Metavention, Inc. Previously, Tony was the Senior Vice President of Product Development and General Manager at Devicix, a multi-disciplinary engineering firm that delivers innovative design solutions and comprehensive product development services to the medical device industry. Prior to Devicix, Tony spent over 20 years in the Cardiovascular Division of Boston Scientific in engineering and leadership positions of increasing responsibility and was most recently the Director of Research and Development for Peripheral Interventions and Hypertension. Tony holds a Bachelors of Mechanical Engineering degree from the University of Minnesota.

Bottom Angle
Top Angle

Scientific Advisors

  • Alan Cherrington, PhD — Professor, Vanderbilt University
  • Robert Smith, MD — Professor, Brown University
  • David Cummings, MD — Professor of Medicine, University of Washington
  • Robert Rizza, MD — Professor of Medicine, Division of Endocrinology, Diabetes, Nutrition, and Metabolism, Mayo Clinic
  • John Buse, MD, PhD — Chief of Endocrinology, University of North Carolina
  • John Amatruda, MD — Adjunct Professor of Medicine, Yale University, former SVP and Franchise Head for Diabetes and Obesity, Merck
  • Scott Vafai, MD — Metavention Co-founder, Director, Mitochondrial Therapeutics Accelerator, Broad Institute of MIT and Harvard
  • Dan Pratt, MD — Clinical Director, Liver Transplantation, Massachusetts General Hospital
  • Marian K. Rippy, D.V.M., Ph.D., A.C.V.P. – Clinical pathologist
Bottom Angle

The Metabolic Neuromodulation System is not currently approved in any region and is limited to investigational use only for the COMPLEMENT study. CAUTION: INVESTIGATIONAL DEVICE, LIMITED TO INVESTIGATIONAL USE.